Diagnostic challenges in vacuolar myelopathy: a didactic case report.

Ernst, F; Klausner, F; Kleindienst, W; Bartsch, H; Taylor, N; Trinka, E; Spinal Cord Ser Cases. 2016; 2: 16020

Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6)

Rinnerthaler, G; Gampenrieder, SP; Voskova, D; Petzer, A; Hubalek, M; Petru, E; Hartmann, B; Andel, J; Balic, M; Melchardt, T; Ulmer, H; Mlineritsch, B; Greil, R CANCER RES. 2017; 77:

Efficacy and safety of the therapeutic cancer vaccine tecemotide (L-BLP25) in early breast cancer: Results from a prospective, randomized, neoadjuvant phase-II study (ABCSG-34)

Singer, CF; Pfeiler, G; Hubalek, M; Bartsch, R; Stoeger, H; Pichler, A; Petru, E; Greil, R; Rudas, M; Tea, MK; Wette, V; Petzer, AL; Sevelda, P; Egle, D; Dubsky, PC; Balic, M; Tinchon, C; Bago-Horvath, Z; Frantal, S; Michael, G CANCER RES. 2017; 77:

DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer

Gampenrieder, SP; Rinnerthaler, G; Pulverer, W; Weinhusel, A; Hufnagl, C; Hackl, H; Hauser-Kronberger, C; Mlineritsch, B; Greil, R CANCER RES. 2017; 77:

TIGIT as a new target for checkpoint inhibition for chronic lymphocytic leukemia

Catakovic, K; Gassner, F; Rathswohl, C; Greil, R; Hartmann, T; Geisberger, R LEUKEMIA LYMPHOMA. 2017; 58: 53-54.

Casein Kinase 1 delta/epsilon inhibition blocks CLL chemotaxis and delays leukemia onset in the E mu-TCL1 mouse model of chronic lymphocytic leukemia

Janovska, P; Verner, J; Kohoutek, J; Bryjoval, L; Dzimkova, M; Skabrahova, H; Radaszkiewicz, T; Nemcova, T; Hoferova, Z; Vasickova, K; Smyckova, L; Gregorova, M; Egle, A; Pavlova, S; Poppova, L; Pospisilova, S; Bryja, V LEUKEMIA LYMPHOMA. 2017; 58: 210-211.

R-EFECT: A multicenter, retrospective evaluation of CML therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting

Petzer, A; Herndlhofer, S; Weltertnann, A; Sliwa, T; Schmidt, S; Greil, R; Wolfler, A; Wiesholzer, M; Dormann, C; Thaler, J; Tinchon, C; Ruckser, R; Lang, A; Hanig, J; Winiger, I; Muenchmeier, N; Sperr, WR ONCOL RES TREAT. 2017; 40: 58-58.

INSIDE-OUT VLA-4 INTEGRIN ACTIVATION IS MAINTAINED IN IBRUTINIB-TREATED CHRONIC LYMPHOCYTIC LEUKEMIA EXPRESSING CD49D: CLINICAL RELEVANCE

Tissino, E; Benedetti, D; Herman, SE; ten Hacken, E; Ahn, IE; Chaffee, KG; Rossi, FM; Dal Bo, M; Bulian, P; Bomben, R; Bayer, E; Harzschel, A; Gutjahr, JC; Postorino, M; Santinelli, E; Ayed, A; Zaja, F; Chiarenza, A; Chigaev, A; Sklar, LA; Burger, JA; Ferrajoli, A; Shanafelt, TD; Wiestner, A; Del Poeta, G; Hartmann, TN; Gattei, V; Zucchetto, A HAEMATOLOGICA. 2017; 102: 229-229.

NGS ANALYSIS OF 474 BONE MARROW SAMPLES FROM 157 AML PATIENTS TREATED WITH AZACITIDINE-IMPACT OF AGE ON MUTATIONAL LOAD

Pleyer, L; Gassner, FJ; Burgstaller, S; Wedler, H; Hartmann, TN; Jansko, B; Neureiter, D; Thaler, J; Greil, R HAEMATOLOGICA. 2017; 102: 215-216.

Low expression of miR-20a-5p predicts benefit to bevacizumab in metastatic breast cancer patients treated within the TANIA trial

Gampenrieder, SP; Rinnerthaler, G; Hackl, H; Steiner, M; Fuentes, CM; Hufnagl, C; Hauser-Kronberger, C; Egle, A; Greil, R ANN ONCOL. 2017; 28: